Business Wire

Panasonic and Institute of Microchemical Technology Co., Ltd. Jointly Develop Mass Production Technology for Microfluidic Devices by Glass Molding, a First in the Industry*1

Share

Panasonic Corporation (Panasonic) and Institute of Microchemical Technology Co., Ltd. (IMT) jointly developed a technology for mass production of microfluidic devices*2 using a glass molding. Compared to the conventional glass etching method, this technology realizes low cost (about 1/10) and highly accurate (about 10 times) mass production. These devices can be applied to sensing and analysis for medical, biological, environmental (water and air quality) applications, etc. The companies will start accepting prototype orders from FY2019, and are planning to start mass production from FY2020. Panasonic and IMT will present and exhibit this device at the 40th meeting of Society for Chemistry and Micro-Nano Systems (CHEMINAS 40th) held at Act City Hamamatsu in Hamamatsu City, Shizuoka Prefecture, Japan from November 19th to 21st.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105006302/en/

Microfluidic device technology (Graphic: Business Wire)

Microfluidic device technology (Graphic: Business Wire)

[Effect]
Conventional glass microfluidic devices have not been widely used, because of high cost and poor precision. This development achieved mass production and cost reduction of glass microfluidic devices by combining IMT's microfluidic device design technology and Panasonic's glass molding technology. As a result, disposable use of glass microfluidic devices becomes possible. In addition, by realizing high precision, it is easy to incorporate the device as a part of equipment and systems.

[Application]
By taking advantage of the environmental and chemical resistance of glass microfluidic devices, it can be applied to environmental sensing, blood testing, and pharmaceutical equipment as disposable detection devices for analysis and testing in outdoor and harsh environments.

[Characteristic]
The newly developed microfluidic device has the following features.
1. Up to φ50mm size
2. More than 10,000 devices per month of production capacity
3. Manufacturing process with the shape precision of about 1μm

[Technology]
This development is realized by the following technologies.
(1) Design and interface technology of microfluidic device optimized for glass molding
(2) Microstructure mold processing technology to higher hardness material and microstructural glass molding technology to precisely transfer to glass
(3) Thermal bonding technology to join a flat glass plate and a plate with microstructures.

Notes:
*1: As of November 6, 2019, Panasonic survey
*2: A device that can perform various chemical processes (mixing, reaction, extraction, synthesis, detection) in a minute flow path with a small amount and high efficiency by flowing liquid through a groove with a width and depth of several hundreds of micrometers.

[Background]
General microfluidic device made of glass used in microfluidics technology [1] is mainly produced by etching techniques. After drawing the flow path pattern by photolithography, the glass flow path is formed by etching, and the cover glass with the machined introduction hole is bonded. Since the inception of this field, IMT has provided high-level products as a pioneer in the planning, design and manufacture of glass microfluidic devices. However, in addition to the skill required for manual manufacturing, the manufacturing process took several months. For this reason, the manufacturing time and cost per piece became a hurdle, and generalization and industrial mounting were not realized, and the use was limited mainly to basic research applications.

On the other hand, Panasonic has been developing and manufacturing glass molding technology [2] from the 1980s, that has contributed to the commercialization of the world's highest level of optical device. They are used in lenses for various optical devices, like digital still cameras.

By combining Panasonic's glass molding technology and IMT design technology, it became possible to develop microstructure mold machining technology, molding technology, and joining technology suitable for mass production of microfluidic devices using glass molding technology. The companies have succeeded in developing mass production technology for microfluidic devices. As a result, it is possible to reduce the cost to about 1/10 compared to the conventional manufacturing method, and to supply glass microfluidic devices with improved precision 10 times or more in less than half the delivery time.

[Practical realization]
With the development of mass production technology for microfluidic devices [3] using this glass molding technology, glass microfluidic devices are widely used as disposable detection devices for analysis and testing in outdoor and harsh environments, and for disposable devices for blood testing equipment.

[Explanation of terms]
[1] Microfluidic device technology
This technology integrates chemical processes such as mixing, reaction, separation, extraction, synthesis, and detection in a flow channel of several tens to several hundreds of μm created on a substrate (microfluidic device) of several cm square. By freely integrating chemical processes that have been performed in laboratories and factories in the microspace of microfluidic devices, it becomes possible to use energy and space much more efficiently. It is expected to contribute greatly to the evolution of chemical technology in the future. This chemical process integration technology (microfluidic technology) in the micro space was established as a result of research and development of the Kitamori “Integrated Chemistry” project. The project was carried out at Kitamori Lab., Department of Applied Chemistry, School of Engineering, The University of Tokyo, and Kanagawa Academy of Science and Technology (currently Kanagawa Institute of Industrial Science and Technology).

[2] Glass molding technology (mold machining technology, mold protection coating technology, molding technology)

[3] Application examples of microfluidic devices using glass molding technology

About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.

About Institute of Microchemical Technology
IMT is a pioneer company of microchemical chip technology (microfluidics) and was founded in 2001 as a venture company of the University of Tokyo and Kanagawa Institute of Industrial Science and Technology (formerly Kanagawa Academy of Science and Technology).
IMT manufactures and sells microchemical chips, their peripheral equipment and system devices.

Company Name: Institute of Microchemical Technology Co., Ltd (IMT)
Capital: 100M JPY
Foundation: May 1st, 2001
Address: A-19 AIRBIC, 7-7 Shinkawasaki, Saiwai, Kawasaki, Kanagawa 212-0032 Japan
TEL: +81-44-201-9889 FAX: +81-44-201-9890
HP: https://www.i-mt.co.jp/en/

Source: https://news.panasonic.com/global/press/data/2019/11/en191106-3/en191106-3.html

Related Links
Industrial Devices & Solutions - Panasonic
https://industrial.panasonic.com/ww

Contact information

Panasonic
Innovation Strategy Office
Technology Public Relations Section
crdpress@ml.jp.panasonic.com

[Inquiries for prototypes]
Institute of Microchemical Technology Co., Ltd.
Email:info@i-mt.co.jp Tel: +81-44-201-9889

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical Association12.11.2019 16:08:00 CETPress release

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).1 Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA). CLEAR Wisdom, a Phase 3, double-blind, randomised trial, evaluated the efficacy, long-term safety and tolerability of bempedoic acid 180 mg versus placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with current lipid-modifying therapies, added on to maximally-tolerated statin therapy, which may mean no statin at all.1 The JAMA publication includes results for the primary efficacy endpoint of low-density lipoprotein cholesterol (LDL-C) lowering at 12 weeks and key secondary endpoints of safety and tolerability over 52

 Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines12.11.2019 15:57:00 CETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that the Regional Pharmaceutical Procurement Service in Northern Ireland has accepted an offer for access to all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Northern Ireland ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will have access to ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations will have access to SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. We will support the arrangements being put in place to ensure clinicians will be able to prescribe to el

Andersen Global Announces First Collaboration in Croatia12.11.2019 14:30:00 CETPress release

Andersen Global announced today that it signed a Collaboration Agreement with one of Croatia’s largest law firms, KALLAY & PARTNERS Ltd. The addition of the Zagreb-based firm establishes Andersen Global’s presence in the country and continues the expansion of the organization in the region. Founded in 2006, KALLAY & PARTNERS Ltd. is led by Founder and Office Managing Director Marko Kallay. Under his leadership, the firm provides both foreign and domestic clients with a broad range of legal services, including banking and finance, commercial and corporate law, dispute settlement, arbitration and mediation, labor law, and regulator relationships. “Our firm values commitment, transparency, reliability and providing clients with the best-in-class legal services, and these values align well with Andersen Global’s standards and vision,” said Marko. “This collaboration will allow us to take our client service to the next level and expand our footprint more broadly. We are excited to work clos

Report: The Delivery Economy Uncovering Misalignment In the Supply Chain12.11.2019 14:00:00 CETPress release

The rapid growth of the Delivery Economy — the pervasive sentiment in which customers expect low-cost, fast and highly transparent delivery of goods — is pressuring companies to quickly address structural supply chain challenges that make it difficult for them to meet increasing customer demands, according to a new report from project44, the global leader in advanced visibility for shippers and logistics service providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005320/en/ (Graphic: Business Wire) The new report from project44, “Aligning the Supply Chain In The Age Of The Delivery Economy,” is based on a blind survey of 300 supply chain professionals. It is the second in a series of reports examining the emergence and impact of the Delivery Economy. The report highlights key issues plaguing both B2B and B2C supply chains and preventing adoption of the organization-wide delivery strategies that will be critical t

Modern Governance 8.0: New Report from Stanford’s Rock Center and Diligent Institute Reveals Corporate Directors Are Less Shareholder-Centric and Success Is No Longer Defined Solely by Shareholder Returns12.11.2019 14:00:00 CETPress release

In a new report released today, Diligent Institute and the Rock Center for Corporate Governance at Stanford University found that board directors consider both shareholder and stakeholder needs when making strategic decisions – reinforcing a stakeholder movement that embraces modern governance. The report, “Stakeholders Take Center Stage: Director Views on Priorities and Society,” includes responses and interviews with nearly 200 directors of public and private corporations globally. According to the survey, a vast majority of corporate directors (89%) believe it is important or very important for their company to consider the interests of non-shareholder stakeholders – such as employees, local communities, and the general public – as they work to achieve business objectives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005426/en/ The findings of this report echo the sentiments of the recent Business Roundtable “Stat

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised12.11.2019 13:36:00 CETPress release

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes when initiated in people hospitalised for any type of acute heart failure event once they have been stabilised. The study will include participants both with and without type 2 diabetes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005650/en/ Heart failure is the leading cause of hospitalisation in Europe and the US, and half of people with heart failure are expected to die within five years of diagnosis.2,3 However, outcomes for patients after they have been hospitalised for heart failure are poor, with a 15 percent mortality and 30 percent readmission rate within 60 to 90 days of discharge from hospital.4 Initiating treatment in